We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Fate Therapeutics Inc | NASDAQ:FATE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.08 | 3.18 | 5.05 | 0 | 09:00:04 |
TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th, 2024 at 9:10 AM ET in Boston, Massachusetts
Leerink Global Biopharma Conference on Monday, March 11th, 2024 at 2:00 PM ET in Miami, Florida
Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12th, 2024 at 11:15 AM ET in Miami, Florida
Jefferies Biotech on the Bay Summit on Wednesday, March 13th, 2024 in Miami, Florida
2nd Annual H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 3:00 PM ET
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina.tartaglia@sternir.com
1 Year Fate Therapeutics Chart |
1 Month Fate Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions